Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Sana Biotechnology, Inc. SANA
$6.30
-$0.18 (-2.78%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1159974948.00000000
-
week52high
9.55
-
week52low
2.99
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.62027000
-
EPS
-1.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 17 мая 2022 г. |
| Goldman Sachs | Neutral | Neutral | 06 авг 2021 г. |
| Morgan Stanley | Overweight | 01 мар 2021 г. | |
| JP Morgan | Neutral | 01 мар 2021 г. | |
| Goldman Sachs | Neutral | 01 мар 2021 г. | |
| Goldman Sachs | Neutral | Neutral | 03 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bishop Hans Edgar | A | 5753172 | 6702 | 05 янв 2023 г. |
| NELSEN ROBERT | A | 1353 | 536 | 05 янв 2023 г. |
| Bishop Hans Edgar | A | 5746470 | 4012 | 05 окт 2022 г. |
| NELSEN ROBERT | A | 817 | 321 | 05 окт 2022 г. |
| Cassidy Bernard J | A | 800000 | 800000 | 15 сент 2022 г. |
| NELSEN ROBERT | A | 496 | 266 | 05 июл 2022 г. |
| Bishop Hans Edgar | A | 5742458 | 3328 | 05 июл 2022 г. |
| MacDonald James J. | D | 51954 | 66796 | 13 июн 2022 г. |
| MacDonald James J. | A | 497396 | 66796 | 13 июн 2022 г. |
| Bilenker Joshua H. | A | 65000 | 65000 | 06 июн 2022 г. |
Новостная лента
4 Penny Stocks To Watch With High Short Interest In January 2023
PennyStocks
27 янв 2023 г. в 12:14
Are these penny stocks ready to squeeze? The post 4 Penny Stocks To Watch With High Short Interest In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?
PennyStocks
13 янв 2023 г. в 19:21
Short squeeze penny stocks to watch this month. The post 4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 16:05
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
7 Unknown Biotech Stocks That Could Rocket in 2023
InvestorPlace
23 сент 2022 г. в 07:30
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
Sana Biotechnology to Present at September 2022 Investor Conferences
GlobeNewsWire
09 сент 2022 г. в 16:05
SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.